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I am most honored to be asked to contribute to the Asian
Journal of Urology (AJU). For many years Asian urologists
and investigators have provided major contributions to
Urology. I applaud and salute this great moment. This new
Journal will serve the world in so many unique ways, and
we are proud to be part of this most historical moment.
In 2015, the Brady Urological Institute at Johns Hopkins
will celebrate its 100 year anniversary. For half of that cen-
tury, I was privileged to be the ResearchDirector. I amnow82
years of age, and very excited to have been replaced by the
talented Dr Kenneth Pienta. He has been our new leader for
several years and joins me in saluting you.
The new AJU will provide a fresh forum for urological
studies originating in Asia as well as the international
urology community. This Journal will most certainly provide
a much needed new perspective to the field of Urology.
With this perspective in view, I hope I might in some way
serve this new Journal. I will try to sum up a few of my
observations and experiences collected over my 50 years of
research focused on the prostate. I will present here only
12 points. Many of the more senior leaders and readers will
already know them well. I hope that these few observations
may serve as clues to challenge new and young in-
vestigators working on “The Riddle of Cancer.” Almost one
out of four people on this planet will suffer from this most
devastating disease. Many will have a urological form of
cancer. We need far more progress. This goal deserves ourE-mail address: dcoffey@jhmi.edu.
Peer review under responsibility of Chinese Urological Associa-
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article under the CC BY-NC-ND license (http://creativecommons.org/libest efforts and we must work even more closely together.
The AJU will be a major beacon in this effort. I am a bit old
to be a good guide but I am honored to join your march.
I highlight below many of my thoughts only for emphasis
and hopefully will help guiding our future understanding of
cancer through new discoveries.
2. Question 1: Of the thousands of mammalian
species on earth, none will develop lethal
prostate cancers with advanced age except for
humans and dogs. Why might this be so?
It appears that the dog and human markedly changed their
diets and activity over the course of evolution as they came
together in ancient tribes and early villages. Ancient humans
markedly changed their life style with farming, herding, an-
imal domestication, cooking, and preserving meat by salting
and smoking. This was combined with a far more sedentary
life. All of this first occurred only about 15,000 years ago over
the last 7% of homosapiens history of 200,000 years. All of
these new human life style changes are now known to be
important factors clearly associated with increased cancer
incidence. These include obesity, lack of activity, smoking,
inflammation, burning meat, and many known and unknown
carcinogens. The domesticated dog shared much of the early
human environment and this included diet and life style. In
addition the dog shows a unique synergism in combining es-
trogens with dihydrotestosterone (DHT) which markedly in-
creases abnormal prostate growth [1]. It is important to note
that only the human and dog also suffer from benign prostate
hyperplasia (BPH) [2e4]. In both species prostatic inflam-
mation is also prominent.n and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
censes/by-nc-nd/4.0/).
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tremendous difference in the organ specificity
of human cancer for the prostate and not for
the seminal vesicles?
In the United States there is a million fold difference in
lifetime mortality risk between prostate cancer and semi-
nal vesicle cancer (Fig. 1). In the United States 3% of all
living males will ultimately die from prostate cancer. This
totals over 4 million men at risk. In comparison, less than 10
men will die from primary seminal vesicle cancer. This is in
spite of many similarities shared between the prostate and
seminal vesicle gland including inheritance, environment,
diet, life style, aging, blood androgen levels and other
shared biological factors (Table 1). Several differences
could be involved: (1) Animals like the dog that eat meat do
not have seminal vesicles. The exception is the human who
has a seminal vesicle and eats meat, but as mentioned the
human diet changed remarkably during evolution. (2) The
prostate, but not the seminal vesicles, is associated with
inflammation that could damage the DNA [5]. Most impor-
tantly, Dr Marikki Laiho at Hopkins has many classical pa-
pers reporting marked differences in the DNA repair
mechanisms between the two glands that favors DNA repair
in the seminal vesicles [6,7].
4. Question 3: If evolution drives all life forms,
and cancer is reported to be a reactivation of
evolution from an adult somatic cell, then how
does this work? (We don’t really understand allFigure 1 Of the entire population of males living today within
cancer within their lifetime. This would calculate to a value of 4.35
increases markedly with aging and as life expectancy increases, s
primary seminal vesicles cancer is an extremely rare event with ver
It is safe to state that less than 100 primary cancer cases have bee
seminal vesicles commonly occur from prostate and bladder cance
cells can invade, survive, and grow within the seminal vesicles [6]aspects of evolution at the molecular level,
particularly the phase shifts and reactivation.)
Brief overview of evolution: All of the many animal and
plant species and life forms on earth, including all 100
trillion cells in our bodies, as well as all cancer cells,
originated at one time from the same singularity, one
ancient cell that formed about 3.9 billion years ago. This
was the first and last cell common to all life.
Much later only 7 million years ago, apes, chimps and our
earliest primate descendants all had a common ancestor,
and then they separated as new species. All modern humans,
Homosapiens, originated only about 200 thousand years ago
in Africa, and then spread rapidly across the planet. The
most ancient dynasties are all far less than 15,000 years old.
We are all out of Africa and related in some manner and
the DNA shows it, butwhat a complex geneticmixturewe are.
We all know that each of the many breedings of our ancestors
combined two selected germ cells to fertilize into a zygote,
where no two germ cells have been alike in each donor pool
because of the extensive multiple crosses between the
meiotic chromatids. The specificity is thatmost genes come in
pairs. There is another DNA specificity in that our mitochon-
drial DNA can only be inherited from the mother. In contrast,
the Y chromosome DNA and the X chromosome are only single
copy in the male and in the prostate. This is a complex DNA
pool in humans. Even siblings can be very different.
Evolution involves sex to combine two germ cells that
provide embryos that develop for 9 months, and this pro-
vides an internal selection process that is like evolution.
This development and pregnancy selection, if successful,the United States, 3% will ultimately die from lethal prostate
million with a lifetime risk of dying from this cancer. This risk
o will these total deaths increase. In comparison, death from
y few primary cases ever being reported in the world literature.
n reported [6]. In contrast, many secondary metastases to the
r cell invasions. This demonstrates that other types of cancer
.
Table 1 The most scholarly review and classical research
reported on the comparison of the marked difference be-
tween the incidence of cancer in the seminal vesicles and
prostate comes from the laboratory of Dr Marikki Laiho [6].
The difference appears to implicate the types of develop-
ment and epigenetic differences that alter DNA damage and
DNA repair.
6 D.S. Coffeycan produce a surviving live birth. The helpless infant must
be protected and nurtured for a dozen years before it can
mature, breed and produce viable off spring. Evolution thus
occurs at many levels.
Somatic cells are NOT directly involved in this evolu-
tionary process. An exception is the immune cells, special
somatic cells that recapitulate and mimic some part of the
evolutionary process by producing genetically variable
clones that are selected and expanded. In some cases im-
mune cells move through the body and attack normal cells,
known as autoimmunity.
Cancer is also a recapitulation of some elements of
evolution in that a single somatic cell develops genetic
instability leading to tumor cell heterogeneity and biodi-
versity that selects clones to survive. The metastatic cell
can destroy the host. No sex or meiosis is involved, but it
must inherit the host nucleus and mitochondria.
5. Question 4: Why don’t identical twins get
identical cancers?
The answer may be that identical twins don’t have identical
DNA, even though they came from the same zygote. Less
than 2% of the total DNA sequence is contained within genes
that can be translated into proteins. The great bulk of the
DNA sequence is in repetitive elements and over 30% of the
sequence is in some form of ancient transposons that can
move around within the genome. These repetitive elements
and transposons are just being sequenced and their func-
tion is just being revealed.
In addition, all of the DNA is constantly undergoing local
repair to correct errors as are the many types of RNA that
are being edited, folded and spliced.
Epigenetic control of DNA expression and RNA function is
now apparent. Epigenetics is driven in part by themethylation of DNA which can be both inherited and tran-
sient. Though one identical twin gets prostate cancer, 60%
of monozygotic identical twins will NOT get lethal prostate
cancer. It is now certain that IDENTICAL TWINS DO NOT
HAVE IDENTICAL DNA. The explanation for this difference
observed in identical twins limits how we analyze our ge-
netic information for the individual, and helps explain why
they don’t share identical types of cancers too often.
Recent information shows that NO TWO CELLS
SEQUENCED FROM AN INDIVIDUAL CANCER ARE ALIKE IN
THEIR GENOTYPE, OR PHENOTYPE!
6. Question 5: Can we develop a DNA barcode
for prostate cancer that predicts lethal disease
early enough to effectively treat it?
We are now riding on a growing tsunami of digitized infor-
mation that is flooding the senses of both the physician and
patient. Can it be simplified, understood, and managed in a
quick manner? Yes! To better understand information
transfer refer to the definitive review in the book: The In-
formation by James Gleick [8].
The average supermarket has about 25,000 store items,
and your cells have about 25,000 genes. The information in
store for each item is contained on a one inch barcode with
about 30 different bars. Each bar is selected from a variety
of 10 different bar widths (representing the numbers 0e9).
The available combinations of numbers from these barc-
odes are therefore 10 to the 30th power (a number equal to
[10 billion  10 billion  10 billion]). This total possible
number combinations that could be represented by the
simple store barcode is so massive it could potentially code
for any conceivable item that will ever be made on this
earth, with millions of information features on each of the
individual items. Today, with this simple store barcode, we
can process individual information on each item in only a
fraction of a second. This happens every day at any com-
mon checkout counter.
The same technique is now in place for a DNA barcode.
The DNA in each cell is two meters in length and contains a
four code system (ATGC) and has 3 billion base pair bars in
each cell. Compared to the 30 bars in the store barcode,
this would be enough information to code for 4 to the 3
billionth power. This is far too much information to ever
be conceived. Can the DNA barcode be simplified? Read
on.
There is now a BARCODE OF LIFE (Fig. 2) that will
identify any of the millions of different animal species on
this planet earth, by just scanning the order of ATGC nu-
cleotides in a very minute fragment of DNA that is just
composed of a total of only 17 nucleotides [7]!! This special
gene that contains this special 17 nucleotide fragment is
found within the mitochondrial gene that codes for CO-1,
an abbreviation for CYTOCHROME OXIDASE complex-1.
This CO-1 enzyme is essential to animals that get their
energy from mitochondria. The CO-1 is not in land plants
that use chlorophyll instead of mitochondria. Land plants
and bacteria have their own special barcode of DNA.
Dr John Petros, a urologist at Emory University in
Atlanta, Georgia, has been a major leader in studying
mitochondrial DNA in urological samples [9].
Figure 2 The sequence of the cytochrome oxidase CO-1 gene in a region of only 17 nucleotides is sufficient to identify the vast
number of animal species on the earth. This is one of the BARCODES OF LIFE (see this figure and discussion in the October, 2008
issue of Scientific America).
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cancer that can be detected in small DNA fragments in the
blood or in non-invasive liquid biopsies from the urine or
semen. It is easily applied to individual cells in the blood
like circulating tumor cells (CTCs).
It is hoped it will be possible to detect lethal prostate
cancer very early by a “field effect” outside the tumor
areas seen by the pathologist (Fig. 3).Figure 3 It is now apparent that many types of prostate cancers
“Kitty Cats”). In contrast, some forms of prostate are very aggres
early field changes in a normal appearing prostate gland that can p
There is growing evidence that this may be possible.7. Question 6: Can high throughput pathology
detect lethal cancer in prostate samples that
look “normal” to present day pathologists?
This has been reported by using quantitative nuclear
morphology by Dr Peter Gann [10], and see review by Dr
Robert Veltri [11]. Other techniques have applied a very
high resolution light microscope using back reflection, andwill never progress to a state that will be lethal (termed here
sive and will later be lethal (termed “Tigers”). Are there very
redict that it will later develop into the Tiger Cancer (Type 3)?
Figure 4 Cancer mortality rates vary with time in different
countries. They also vary within locations in each country and
by life style. Since rates change as people move to different
localities, it provides a possibility of informative epidemio-
logical studies to reveal causative factors. The data here are
for 2005 to capture more complete WHO data provided then
through the ACS.
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samples [12]. Flow cytometry on aspirated live cells is
promising [13] as is laser and immunohistochemistry on
CTCs [14].
Dr Leland W.K. Chung and his colleagues have developed
special in vivo dyes that provide fluorescence in the near-
infrared fluorescence spectra and can detect live tumors
by external non-invasive imaging methods [15,16].
8. Question 7: Prostate cancer is specific for
the country you live in, and when you move
your risk adjusts to that of the country youFigure 5 Individual units within a system act in a collective mann
bacteria, and cancer). This emergent module is highly adaptive and
has no leader, and it is a complex adaptive system like an ant hillmove to (Fig. 4). Why? Prostate cancer seems
to be related to a western diet. Why? can we
find the risk factor(s) and can this information
be used to prevent cancer?
It appears that life style trumps genetic inheritance. Stress,
what you eat, how you prepare the food, and the inflam-
mation within the prostate are critical factors related to
prostate cancer [17]. Prostate inflammation from reactive
oxygen or pathogens is an early step in carcinogenesis
[17,18]. In animal models prostate inflammation is pre-
vented by soy in the diet [19]. The microbiome in the gut
influences the active soy metabolism to phytoestrogens
(gentisen) in the intestines (See Fig. 4).
The largest and longest epidemiological study in humans
only shows one dietary factor with a strong association,
CHOLINE [20]. Choline is an essential nutrient in the diet
and is a major one carbon donor to provide the methyl
donor to S-adenosyl methionine (SAM). SAM provides the
critical component for methylating DNA, RNA, and proteins
in many epigenetic events in the body. Dietary choline is a
major step in synthesis of lipids through the essential CDP-
Choline building block. Choline is involved via SAM as the
critical factor in DNA synthesis through nucleotide conver-
sion of uridine to form thymidine by methylation. Choline
also provides methyl groups for the epigenetic modification
events in the cell. For all these reasons, choline is markedly
elevated in many types of cancer as can be seen by MRI
spectra. Therefore, choline is a sensitive PET scanning
agent for metastatic lesions. Since choline is an essential
dietary component and is keyed to cancer, it merits our
attention as a life style factor in cancer.
Other dietary factors involve how overheating meats to
produce the common charcoal stripes introduces a
polycyclic carcinogen that when fed to rats induces cancerer to self-organize into a new module (e.g. flock, city, neurons,
exhibits dynamic plasticity. The communication is essential, it
that comes from one clone.
Evolution in prostate cancer 9of the prostate, breast, or colon but not seminal
vesicles [21].
9. Question 8: Cancers have collective
properties and communication between
cancer cells and host cells. How?
Collective communication and self-organization are most
apparent in ant hills, bee hives, and bacterial colonies
(Fig. 5). It extends to schools of fish, flocks of birds and
cities as well as non-animate systems like snowflakes [22].
This is paramount for group survival and in the case of how
bacteria increases resistance to drugs and stress. Many
fragments of DNA and many types of exosomes and non-
coding RNAs are involved. Early leaders in this field are
Leland W. K. Chung [23,24], Ken Pienta [25,26], Eschel Ben-
Jacob [27,28] and others. TO STOP COLLECTIVE COMMUNI-
CATION IN CANCER WE NEED A CYBER WAR.
10. Question 9: Normal prostates have
inherent homeostasis and with androgen theyFigure 6 This is a study of homeostasis in a normal rat ventral pro
far left in time and following castration, the gland shrinks with loss
synthesis and restores the gland. Then even with androgen and rec
homeostasis does not occur in prostate cancer.grow to a predetermined size and stop growth
(Fig. 6)
No normal prostate in humans or animals becomes castrate
resistant and never regrows in the absence of the testes
(See Fig. 6).
The opposite to the above statements occurs in prostate
cancer where there is no limit on androgen induced growth
and most prostate cancers become resistant to castration
therapy.
(See review by Dr. Donald Tindall on androgen action [29]).
11. Question 10: All factors in normal cells are
ordered by homeostasis. The opposite is true
in cancer cells where everything is varied
(Fig. 7)
To destroy the last cancer cell may be difficult. It may be
better to put it on “PAUSE” by changing its habitat [32,33].
This is what we do to control bacteria and weeds growing in
our lawns (See Fig. 7).state gland. The total DNA represents the total cells. Normal is
of DNA and cells. The restoration of testosterone turns on DNA
eptor, it turns back off when homeostasis is reached [30]. This
Figure 7 Theoretical differences of how normal cells responded differently from cancer cells and their ability to gain therapeutic
resistance. The chaotic cancer cells acquired ability to activate somatic cells, increase to entropy to develop micrometastasis and
aberrant information transformed not normally seen in normal cells [22,31].
10 D.S. CoffeyIt may be possible to pasteurize the cancer cells and
preserve the normal cells. We don’t kill all the bacteria in
the grocery store and food supply, and yet we make it
edible. We should study how this is done and extend it to
cancer control.
12. Question 11: We may have to control
cancer by fighting evolution with synthetic
evolution. This means using a random library
This means letting the cancer select its own drug by using a
random library of synthetic RNA aptamers [34,35]. With
each binding from the library you enrich the homing
aptamer to be amplified for the next round of amplification
and purification. This process is called SELEX. We suggest it
might be effective in controlling tumor cell heterogeneity
and resistant cells. Dr Shawn Lupoldhas made a very
effective aptamer against a PSMA target on the human
prostate cancer cell surface [36]. He has now constructed a
hybrid to knock out the DNA repair enzymes.
13. Question 12: Don’t wait on the computer
The largest supercomputers can store as much information
as your brain and can process it at the same speed. To do
this it requires 10 million W. Your brain can do the same
calculations on only 20 W.
Read the paper titled “The Real Final Exam” [37] and
join this most important project.
Thank you and I wish you all the best of luck.
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